{"id":"https://openalex.org/W2019458035","doi":"https://doi.org/10.1016/j.ejphar.2011.05.050","title":"Functional potencies of dopamine agonists and antagonists at human dopamine D2 and D3 receptors","display_name":"Functional potencies of dopamine agonists and antagonists at human dopamine D2 and D3 receptors","alternate_titles":[],"publication_year":2011,"publication_date":"2011-06-05","ids":{"openalex":"https://openalex.org/W2019458035","doi":"https://doi.org/10.1016/j.ejphar.2011.05.050","mag":"2019458035","pmid":"https://pubmed.ncbi.nlm.nih.gov/21658377"},"language":"en","primary_location":{"id":"doi:10.1016/j.ejphar.2011.05.050","doi":"https://doi.org/10.1016/j.ejphar.2011.05.050","is_oa":false,"landing_page_url":"https://doi.org/10.1016/j.ejphar.2011.05.050","pdf_url":null,"source":{"id":"https://openalex.org/S187816532","display_name":"European Journal of Pharmacology","issn_l":"0014-2999","issn":["0014-2999","1879-0712"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-d","doyens","jufo-2","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"European Journal of Pharmacology","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2019458035"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5028512830","display_name":"Yoshihiro Tadori","orcid":"https://orcid.org/0000-0002-9752-8949","observed_orcids":["https://orcid.org/0000-0002-9752-8949"]},"institutions":[{"id":"https://openalex.org/I114030911","display_name":"Otsuka (Japan)","ror":"https://ror.org/013k5y296","country_code":"JP","type":"company","lineage":["https://openalex.org/I114030911"]}],"countries":["JP"],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"Yoshihiro Tadori","raw_affiliation_strings":["Quests Research Institute, Otsuka Pharmaceutical Co., Ltd., Tokushima, 771-0192, Japan. y_tadori@research.otsuka.co.jp","Quests Research Institute, Otsuka Pharmaceutical Co., Ltd., Tokushima, 771-0192, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Quests Research Institute, Otsuka Pharmaceutical Co., Ltd., Tokushima, 771-0192, Japan. y_tadori@research.otsuka.co.jp","institution_ids":["https://openalex.org/I114030911"]},{"raw_affiliation_string":"Quests Research Institute, Otsuka Pharmaceutical Co., Ltd., Tokushima, 771-0192, Japan","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110034011","display_name":"Robert A. Forbes","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210086062","display_name":"Otsuka (United States)","ror":"https://ror.org/00ew4na22","country_code":"US","type":"company","lineage":["https://openalex.org/I114030911","https://openalex.org/I4210086062"]},{"id":"https://openalex.org/I4405268153","display_name":"Otsuka Pharmaceutical Development & Commercialization, Inc. (United States)","ror":"https://ror.org/001nxvg84","country_code":"US","type":"company","lineage":["https://openalex.org/I4405268153"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Robert A. Forbes","raw_affiliation_strings":["Otsuka Pharmaceutical Development & Commercialization, Inc., Princeton, NJ, 08540, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Otsuka Pharmaceutical Development & Commercialization, Inc., Princeton, NJ, 08540, USA","institution_ids":["https://openalex.org/I4210086062","https://openalex.org/I4405268153"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108358185","display_name":"Robert D. McQuade","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210086062","display_name":"Otsuka (United States)","ror":"https://ror.org/00ew4na22","country_code":"US","type":"company","lineage":["https://openalex.org/I114030911","https://openalex.org/I4210086062"]},{"id":"https://openalex.org/I4405268153","display_name":"Otsuka Pharmaceutical Development & Commercialization, Inc. (United States)","ror":"https://ror.org/001nxvg84","country_code":"US","type":"company","lineage":["https://openalex.org/I4405268153"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Robert D. McQuade","raw_affiliation_strings":["Otsuka Pharmaceutical Development & Commercialization, Inc., Princeton, NJ, 08540, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Otsuka Pharmaceutical Development & Commercialization, Inc., Princeton, NJ, 08540, USA","institution_ids":["https://openalex.org/I4210086062","https://openalex.org/I4405268153"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5062112121","display_name":"Tetsuro Kikuchi","orcid":"https://orcid.org/0000-0002-3902-7302","observed_orcids":["https://orcid.org/0000-0002-3902-7302"]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Tetsuro Kikuchi","raw_affiliation_strings":["Quests Research Institute, Otsuka Pharmaceutical Co., Ltd., Tokushima, 771-0192, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Quests Research Institute, Otsuka Pharmaceutical Co., Ltd., Tokushima, 771-0192, Japan","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":3,"corresponding_author_ids":["https://openalex.org/A5028512830"],"corresponding_institution_ids":["https://openalex.org/I114030911"],"apc_list":{"value":3230,"currency":"USD","value_usd":3230},"apc_paid":null,"fwci":1.9177,"has_fulltext":false,"cited_by_count":73,"citation_normalized_percentile":{"value":0.85807243,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":86,"max":99},"biblio":{"volume":"666","issue":"1-3","first_page":"43","last_page":"52"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11178","display_name":"Receptor Mechanisms and Signaling","score":0.8353999853134155,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11178","display_name":"Receptor Mechanisms and Signaling","score":0.8353999853134155,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10056","display_name":"Neurotransmitter Receptor Influence on Behavior","score":0.15379999577999115,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10077","display_name":"Neuroscience and Neuropharmacology Research","score":0.00279999990016222,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/dopamine-d2-receptor","display_name":"dopamine D2 receptor","score":0.8820000290870667},{"id":"https://openalex.org/keywords/dopamine-d3-receptor","display_name":"dopamine D3 receptor","score":1.0},{"id":"https://openalex.org/keywords/dopamine-agonists","display_name":"dopamine agonists","score":0.8899999856948853},{"id":"https://openalex.org/keywords/dopamine-receptor-antagonists","display_name":"dopamine antagonists","score":0.9860000014305115},{"id":"https://openalex.org/keywords/antiparkinsonian-drugs","display_name":"antiparkinsonian drugs","score":0.7960000038146973},{"id":"https://openalex.org/keywords/antipsychotic-drugs","display_name":"antipsychotic drugs","score":0.9869999885559082},{"id":"https://openalex.org/keywords/aripiprazole","display_name":"aripiprazole","score":0.9549999833106995},{"id":"https://openalex.org/keywords/cabergoline","display_name":"cabergoline","score":0.8289999961853027},{"id":"https://openalex.org/keywords/bromocriptine","display_name":"bromocriptine","score":0.9890000224113464},{"id":"https://openalex.org/keywords/pergolide","display_name":"pergolide","score":0.9900000095367432},{"id":"https://openalex.org/keywords/pramipexole","display_name":"pramipexole","score":0.8190000057220459},{"id":"https://openalex.org/keywords/talipexole","display_name":"talipexole","score":0.8659999966621399},{"id":"https://openalex.org/keywords/7-oh-dpat","display_name":"7-OH-DPAT","score":0.8550000190734863},{"id":"https://openalex.org/keywords/ropinirole","display_name":"ropinirole","score":0.8569999933242798},{"id":"https://openalex.org/keywords/camp-accumulation","display_name":"cAMP accumulation","score":0.47999998927116394}],"concepts":[{"id":"https://openalex.org/C2778717949","wikidata":"https://www.wikidata.org/wiki/Q415752","display_name":"Pergolide","level":5,"score":0.7115229368209839},{"id":"https://openalex.org/C199596767","wikidata":"https://www.wikidata.org/wiki/Q21110872","display_name":"Dopamine receptor D3","level":4,"score":0.6620214581489563},{"id":"https://openalex.org/C2778938600","wikidata":"https://www.wikidata.org/wiki/Q389934","display_name":"Agonist","level":3,"score":0.6462430953979492},{"id":"https://openalex.org/C44208683","wikidata":"https://www.wikidata.org/wiki/Q15335165","display_name":"Dopamine receptor D2","level":3,"score":0.6214199662208557},{"id":"https://openalex.org/C58732023","wikidata":"https://www.wikidata.org/wiki/Q770260","display_name":"Partial agonist","level":4,"score":0.6184271574020386},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.5425330996513367},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.5392540693283081},{"id":"https://openalex.org/C2778258207","wikidata":"https://www.wikidata.org/wiki/Q600203","display_name":"Dopamine agonist","level":4,"score":0.5297770500183105},{"id":"https://openalex.org/C513476851","wikidata":"https://www.wikidata.org/wiki/Q170304","display_name":"Dopamine","level":2,"score":0.5186282992362976},{"id":"https://openalex.org/C2779989193","wikidata":"https://www.wikidata.org/wiki/Q421304","display_name":"Pramipexole","level":4,"score":0.5138623714447021},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4854141175746918},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.48520925641059875},{"id":"https://openalex.org/C2776856834","wikidata":"https://www.wikidata.org/wiki/Q413581","display_name":"Bromocriptine","level":4,"score":0.4757623076438904},{"id":"https://openalex.org/C120069818","wikidata":"https://www.wikidata.org/wiki/Q415496","display_name":"Dopamine receptor","level":3,"score":0.46121490001678467},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.2738375663757324},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.19713696837425232},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.15904054045677185},{"id":"https://openalex.org/C2779064019","wikidata":"https://www.wikidata.org/wiki/Q66590068","display_name":"Prolactin","level":3,"score":0.11718392372131348},{"id":"https://openalex.org/C2779734285","wikidata":"https://www.wikidata.org/wiki/Q11085","display_name":"Parkinson's disease","level":3,"score":0.054112374782562256},{"id":"https://openalex.org/C71315377","wikidata":"https://www.wikidata.org/wiki/Q11364","display_name":"Hormone","level":2,"score":0.04962459206581116},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D000068180","descriptor_name":"Aripiprazole","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000242","descriptor_name":"Cyclic AMP","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D003412","descriptor_name":"Cricetulus","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005576","descriptor_name":"Colforsin","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D006224","descriptor_name":"Cricetinae","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010879","descriptor_name":"Piperazines","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D015363","descriptor_name":"Quinolones","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D016466","descriptor_name":"CHO Cells","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017448","descriptor_name":"Receptors, Dopamine D2","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D017448","descriptor_name":"Receptors, Dopamine D2","qualifier_ui":"Q000819","qualifier_name":"agonists","is_major_topic":false},{"descriptor_ui":"D018491","descriptor_name":"Dopamine Agonists","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D018492","descriptor_name":"Dopamine Antagonists","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D050637","descriptor_name":"Receptors, Dopamine D3","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":false},{"descriptor_ui":"D050637","descriptor_name":"Receptors, Dopamine D3","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D050637","descriptor_name":"Receptors, Dopamine D3","qualifier_ui":"Q000819","qualifier_name":"agonists","is_major_topic":false},{"descriptor_ui":"D065127","descriptor_name":"Dopamine D2 Receptor Antagonists","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1016/j.ejphar.2011.05.050","doi":"https://doi.org/10.1016/j.ejphar.2011.05.050","is_oa":false,"landing_page_url":"https://doi.org/10.1016/j.ejphar.2011.05.050","pdf_url":null,"source":{"id":"https://openalex.org/S187816532","display_name":"European Journal of Pharmacology","issn_l":"0014-2999","issn":["0014-2999","1879-0712"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-d","doyens","jufo-2","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"European Journal of Pharmacology","raw_type":"journal-article"},{"id":"pmid:21658377","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/21658377","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"European journal of pharmacology","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.9537000060081482}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320324177","display_name":"Otsuka Pharmaceutical","ror":"https://ror.org/013k5y296"}],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":42,"referenced_works":["https://openalex.org/W105014248","https://openalex.org/W1539952678","https://openalex.org/W1546116904","https://openalex.org/W1757846929","https://openalex.org/W1967001791","https://openalex.org/W1969378517","https://openalex.org/W1975034617","https://openalex.org/W1990450584","https://openalex.org/W1994429247","https://openalex.org/W2002159489","https://openalex.org/W2002834809","https://openalex.org/W2002993605","https://openalex.org/W2010945210","https://openalex.org/W2028730857","https://openalex.org/W2034629571","https://openalex.org/W2037459031","https://openalex.org/W2046179803","https://openalex.org/W2046293215","https://openalex.org/W2050386004","https://openalex.org/W2058981444","https://openalex.org/W2066520436","https://openalex.org/W2070264532","https://openalex.org/W2074631079","https://openalex.org/W2074925663","https://openalex.org/W2076171715","https://openalex.org/W2077004979","https://openalex.org/W2079068793","https://openalex.org/W2086717751","https://openalex.org/W2090055848","https://openalex.org/W2091812380","https://openalex.org/W2094769668","https://openalex.org/W2104518967","https://openalex.org/W2110971533","https://openalex.org/W2121612791","https://openalex.org/W2125393689","https://openalex.org/W2139879310","https://openalex.org/W2147099798","https://openalex.org/W2152837663","https://openalex.org/W2162345704","https://openalex.org/W2165162816","https://openalex.org/W2167381827","https://openalex.org/W2171259847"],"related_works":["https://openalex.org/W4233619539","https://openalex.org/W1975553491","https://openalex.org/W2070264532","https://openalex.org/W2046179803","https://openalex.org/W2044372141","https://openalex.org/W2094309508","https://openalex.org/W2086717751","https://openalex.org/W2077004979","https://openalex.org/W1973251131","https://openalex.org/W2133608824"],"abstract_inverted_index":null,"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2019458035","counts_by_year":[{"year":2026,"cited_by_count":2},{"year":2025,"cited_by_count":3},{"year":2024,"cited_by_count":1},{"year":2023,"cited_by_count":3},{"year":2022,"cited_by_count":9},{"year":2021,"cited_by_count":3},{"year":2020,"cited_by_count":4},{"year":2019,"cited_by_count":5},{"year":2018,"cited_by_count":8},{"year":2017,"cited_by_count":2},{"year":2016,"cited_by_count":5},{"year":2015,"cited_by_count":8},{"year":2014,"cited_by_count":6},{"year":2013,"cited_by_count":4},{"year":2012,"cited_by_count":7}],"updated_date":"2026-11-20T13:11:24.684918","created_date":"2016-06-24T00:00:00"}
